Fate Therapeutics gets US patent for class of small molecule modulators of Rho-associated kinase
The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are crucial to the therapeutic application of human induced pluripotent stem cells
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.